India's BioPharma SHAKTI Boosts Non-Animal Drug Development

The BioPharma SHAKTI strategy, unveiled in the 2026 Union Budget, represents a critical policy pivot towards bolstering India's biopharmaceutical sector. This initiative correctly identifies the growing global significance of biologics and biosimilars, a class of drugs increasingly vital for chronic disease management. By allocating a substantial ₹10,000 crore, the government signals a serious commitment to domestic production and technological advancement in this high-value domain.

A key strength of this strategy lies in its explicit promotion of Non-Animal Methodologies (NAMs). Past incidents, such as the Northwick Park Tragedy in 2006 involving theralizumab, starkly demonstrated the inherent unreliability of animal models for predicting human drug responses. NAMs, including organoids and 3D bioprinting, offer a scientifically superior and ethically sound alternative, promising not only more accurate safety and efficacy data but also potential reductions in drug development costs and timelines.

However, the successful implementation of BioPharma SHAKTI hinges on overcoming significant systemic hurdles. Despite the New Drugs and Clinical Trials (Amendment) Rules 2023 promoting NAMs, their commercialization remains nascent due to issues of accessibility, sustained funding, and a lack of robust entrepreneurial ecosystem. Merely providing funds is insufficient; a concerted effort is required to build infrastructure, foster skilled human capital, and streamline technology transfer from academia to industry.

Furthermore, regulatory clarity from bodies like the Central Drugs Standard Control Organisation (CDSCO) is paramount. The current draft guidelines for biosimilars, particularly concerning NAMs, require accelerated finalization and clear implementation pathways. Addressing challenges like patent evergreening, which delays the availability of affordable biosimilars, demands proactive government intervention to ensure the policy's intended benefits reach the wider population. India must learn from the U.K.'s roadmap to phase out animal experiments and expedite its own regulatory evolution.